Gelesis’ hydrogel promotes weight loss and metabolic health by targeting the gut-liver axisWeight loss resulting from Gelesis’ superabsorbent hydrogel treatment is not only a result of its space-occupying properties, the...
LIGHT-UP outcomes: GS200 patients lose on average 11% of body weightResults from the LIGHT-UP clinical trial for adults with overweight or obesity who have prediabetes or type 2 diabetes and were treated...
Gelesis announces merger with Capstar SpecialGelesis, a biotherapeutics company advancing biomimetic superabsorbent hydrogels to treat excess weight and metabolic disorders, and...
Plenity induced weight loss results in NALFD fibrosis score improvementA post-hoc analysis showed that treatment for weight management with Plenity decreased a marker for liver fibrosis (the NAFLD fibrosis...
Gelesis gains European approval for PLENITY weight loss treatmentGelesis, a biotechnology company developing a novel hydrogel platform technology to treat obesity and other chronic diseases related to...
GLP-1s associated with higher risk of major depression, increased risk for anxiety and an elevated risk for suicidal behaviour20 hours ago